A 28-year-old woman with generalized tonic-clonic seizures is started on phenytoin 300 mg/day. After 3 weeks of therapy, she develops gum hypertrophy, hirsutism, and coarsening of facial features. She also reports mood changes and difficulty concentrating. Laboratory investigations show normal serum phenytoin levels (15 µg/mL). She is planning to conceive in 6 months. Which of the following is the most appropriate next step?

Explanation

## Clinical Context This patient presents with cosmetic and systemic adverse effects of phenytoin (gum hypertrophy, hirsutism, facial coarsening) despite therapeutic drug levels, plus cognitive effects. Critically, she is a woman of childbearing age planning conception within 6 months. ## Why Levetiracetam is the Best Choice **High-Yield:** Levetiracetam (LEV) is a modern antiepileptic with a superior safety profile in pregnancy and minimal cosmetic/systemic toxicity compared to phenytoin. | Feature | Phenytoin | Levetiracetam | |---------|-----------|---------------| | **Teratogenicity** | Fetal hydantoin syndrome (cleft palate, cardiac defects, IUGR) | Minimal; FDA Pregnancy Category C | | **Cosmetic effects** | Gum hypertrophy, hirsutism, coarsening | Absent | | **Cognitive effects** | Significant (diplopia, ataxia, confusion) | Minimal; mood changes in 1–3% | | **Drug interactions** | Extensive (CYP450 inducer) | Minimal; renal excretion | | **Monitoring** | Therapeutic drug level, gum care, folate | Renal function only | **Key Point:** Phenytoin causes fetal hydantoin syndrome (cleft palate, cardiac anomalies, growth restriction, developmental delay) and is contraindicated in women planning pregnancy. Levetiracetam has no known teratogenic effects and is increasingly used as first-line in women of childbearing potential. **Clinical Pearl:** The patient's adverse effects (gum hypertrophy, hirsutism, facial coarsening) are chronic toxicities of phenytoin unrelated to serum levels — they will not resolve by dose adjustment and may worsen over time. These are strong indicators to switch to a safer agent. ## Why Other Options Are Incorrect **Option A (Continue phenytoin + folic acid):** While folic acid reduces the risk of neural tube defects, it does NOT prevent fetal hydantoin syndrome (facial clefts, cardiac defects, growth restriction). Continuing phenytoin in a woman planning pregnancy is suboptimal. **Option C (Increase phenytoin dose):** The patient already has therapeutic levels (15 µg/mL, normal range 10–20 µg/mL). Increasing dose will worsen cosmetic and cognitive toxicity without improving seizure control and increases teratogenic risk. **Option D (Add carbamazepine):** Carbamazepine is also teratogenic (Ebstein's anomaly, developmental delay) and adds polypharmacy complexity. It does not address the cosmetic toxicity of phenytoin. ## Management Algorithm ```mermaid flowchart TD A["Woman of childbearing age on phenytoin"]:::outcome --> B{"Adverse effects or pregnancy planned?"}:::decision B -->|Yes| C["Switch to LEV, LTG, or oxcarbazepine"]:::action B -->|No| D["Continue current therapy"]:::action C --> E["Taper phenytoin over 2–4 weeks"]:::action E --> F["Start alternative agent at therapeutic dose"]:::action F --> G["Seizure control achieved"]:::outcome ``` [cite:KD Tripathi 8e Ch 10]